Skip to main content
Signal8

BioLineRx Ltd. (BLRX) Form 6-K — Jul 8, 2026

$BLRXForm 6-KFiled Jul 8, 2026, 7:08 AM ET0001178913-26-003438Original filing

BioLineRx and partner Hemispherian announced positive preclinical data showing strong synergy between GLIX1 and the PARP inhibitor olaparib in ovarian cancer models. The combination therapy demonstrated tumor reduction comparable to the chemotherapy benchmark cisplatin, outperforming control and monotherapy arms even at lower doses.

Key figures

Clinical Trial Id
NCT07464925
Hr Proficient Percentage
50%
Phase1 2a Part1 Patients
up to 30
Ovarian Cancer Deaths2026
12450
Ovarian Cancer New Cases2026
21000

AI analysis

The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.

    BioLineRx Ltd. (BLRX) Form 6-K — Jul 8, 2026: AI Analysis | Signal8